Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q2

4886.TEDINET S100PIUD
Period2022-04-01 → 2022-09-30
Filed2022-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥30.2bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥56.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥28.5bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥2.9bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥2.7bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥3.0bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.7bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥3.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥4.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥2.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.8bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income−¥2.8bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥86.2bnat 2022-09-30Cons.Assets
Total assets¥83.3bnat 2022-03-31Cons.Assets
Total assets¥78.3bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥34.2bnat 2022-09-30Cons.Liabilities
Total liabilities¥34.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥52.0bnat 2022-09-30Cons.Net assets
Net assets / equity¥48.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥41.8bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥17.2bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥12.1bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥17.2bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥17.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥10.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥2.8bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥199m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥6.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥427m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥1.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥3.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥83.182022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥36.252022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-98.522021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-137.172021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio60.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio53.4%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥114m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥86m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥28m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥20m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥473m
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥3.2bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥231m
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥30.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥30.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥3.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥93m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥66m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥26m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30−¥26m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥26m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥26m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥342m
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥2.8bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥2.8bn
jpcrp040300-q2r_E35791-000Animal Health Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥229m
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥25.6bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥25.6bn
jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.8bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥28.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥28.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥26m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥3.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 470
ItemContextValueUnit
Ordinary incomeCurrentYTDDuration2987000000JPY
Gain on sales of investment securities eiPrior1YTDDuration－JPY
Gain on sales of investment securities eiCurrentYTDDuration32000000JPY
Extraordinary incomePrior1YTDDuration－JPY
Extraordinary incomeCurrentYTDDuration32000000JPY
Impairment loss elPrior1YTDDuration5921000000JPY
Impairment loss elCurrentYTDDuration－JPY
Other elPrior1YTDDuration961000000JPY
Other elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration6882000000JPY
Extraordinary lossCurrentYTDDuration－JPY
Income before income taxesPrior1YTDDuration-4139000000JPY
Income before income taxesCurrentYTDDuration3019000000JPY
Income taxes currentPrior1YTDDuration117000000JPY
Income taxes currentCurrentYTDDuration693000000JPY
Income taxes deferredPrior1YTDDuration-1460000000JPY
Income taxes deferredCurrentYTDDuration-19000000JPY
Income taxesPrior1YTDDuration-1342000000JPY
Income taxesCurrentYTDDuration673000000JPY
Profit lossPrior1YTDDuration-2796000000JPY
Profit lossCurrentYTDDuration2346000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-2796000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration2346000000JPY
Profit lossPrior1YTDDuration-2796000000JPY
Profit lossCurrentYTDDuration2346000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration162000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration519000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration15000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration13000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration59000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration371000000JPY
Other comprehensive incomePrior1YTDDuration237000000JPY
Other comprehensive incomeCurrentYTDDuration905000000JPY
Comprehensive incomePrior1YTDDuration-2559000000JPY
Comprehensive incomeCurrentYTDDuration3251000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-2559000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration3251000000JPY
Income before income taxesPrior1YTDDuration-4139000000JPY
Income before income taxesCurrentYTDDuration3019000000JPY
Depreciation and amortization ope cfPrior1YTDDuration1346000000JPY
Depreciation and amortization ope cfCurrentYTDDuration1527000000JPY
Impairment loss ope cfPrior1YTDDuration5921000000JPY
Impairment loss ope cfCurrentYTDDuration－JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration221000000JPY
Increase decrease in net defined benefit liability ope cfCurrentYTDDuration132000000JPY
Interest and dividends income ope cfPrior1YTDDuration-137000000JPY
Interest and dividends income ope cfCurrentYTDDuration-185000000JPY
Interest expenses ope cfPrior1YTDDuration29000000JPY
Interest expenses ope cfCurrentYTDDuration25000000JPY
Equity in earnings losses of affiliates ope cfPrior1YTDDuration-51000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass